Menu
Recruiting NCT07041710

Rehabilitation of Taste and Smell Disorders Associated With Chemotherapy Using Aromatherapy

No phase Interventional Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: experimental in day hospital, taste and smell disorders questionnaire.
Who it may be relevant to
Registry conditions: Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Changes in taste and smell can occur during chemotherapy treatment. These chemotherapy-related side effects can negatively impact patients' quality of life and diet. The aim of this research is therefore to propose a solution to alleviate these taste and smell disorders. Based on the same principle as rehabilitation proposed for anosmia (loss of smell) related to COVID-19, we hypothesize that olfactory rehabilitation (using the sense of smell) through the odorous properties of essential oils could be effective for chemotherapy-related taste and smell alterations.

Interventions

  • Other experimental in day hospital
    multidisciplinary day hospital
  • Other taste and smell disorders questionnaire
    Answer to the home-made questionnaire at inclusion and at 6 months

Primary outcome measures

  • difference in scores between 6 months and the inclusion at "taste and smell disorders" questionnaire [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • cancer treated with chemotherapy
  • patient with taste and/or smell disorders

Exclusion criteria

  • patient at the end of chemotherapy treatment

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

France · 1 center
  • Médipôle Hôpital Mututaliste — Villeurbanne

Identifiers

NCT: NCT07041710 · AGORA

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗